Navigation Links
Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
Date:9/8/2008

of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Kurt Leutzinger

CFO

Kurt.leutzinger@pharmasset.com

Office: 609-613-4110

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that the final results of the third and fourth cohorts of the 4-week Phase I clinical trial evaluating R7128 will be materially different from the preliminary results, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from t
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
2. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
3. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
4. Pharmasset Joins Russell 3000 Index
5. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
6. Pharmasset Selected to Join the NASDAQ Biotechnology Index
7. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
8. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
9. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
10. Pharmasset Receives $10 Million of Working Capital
11. Pharmasset Appoints Herbert J. Conrad as a Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... (PRWEB) October 01, 2014 Weighing ... quality of the final product. However, while the ... regulatory frameworks such as Good Manufacturing Practices (GMP) ... responsibility of the manufacturer to interpret these guidelines ... weighing performance quality. METTLER TOLEDO experts have created ...
(Date:10/1/2014)... The participants committed to not only creating ... own time adjusting, tweaking and testing virtual models and ... for judging. , “I enjoyed being involved as a ... “The entries showed a commendable range exploring the technical ... print medium and the creativity of the contestants.” , ...
(Date:10/1/2014)... September 30, 2014 Award winning ... announces four new-hosted collaboration bundles that combine ... high quality conferencing experiences for low, flat rate ... choose from, businesses have optimized solutions to meet ... include audio only minutes (1K, 5K, 10K ...
(Date:10/1/2014)... -- This report analyzes the worldwide markets ... the following Product Segments: Proteases, Polymerases, Carbohydrases, ... also analyzed are Pharmaceuticals & Diagnostics, Research/Biotechnology, ... separate comprehensive analytics for the US, Canada, ... America. Annual estimates and forecasts are provided ...
Breaking Biology Technology:Comply with Weighing-Related Regulations in Pharma Manufacturing 2Array Architects Challenges Staff to Create with 3D Printer 2SoundConnect Launches New Audio, Web and Video Bundles 2Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21Global Specialty Enzymes Industry 22Global Specialty Enzymes Industry 23Global Specialty Enzymes Industry 24Global Specialty Enzymes Industry 25Global Specialty Enzymes Industry 26
... WASHINGTON, Oct. 5 The Coalition for a,Competitive ... the Food and Drug Administration,s announcement regarding its,"Generic ... consumers, employers, insurers, and policymakers grappling with,how to ... that FDA,and Congress continue to focus on ways ...
... Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) today announced that ... officer, will present,at the BIO InvestorForum at The Palace ... at 11:00 a.m. Pacific Time. A live webcast ... at http://www.lexpharma.com . An archived version of the,webcast ...
... Pharmasset, Inc.,(Nasdaq: VRUS ) has entered into ... Subject to certain terms and conditions of,the agreement, Horizon ... At its option, Pharmasset may receive a second loan ... loan of $10 million by November 30, 2008,provided conditions ...
Cached Biology Technology:CCPM Issues Statement on FDA's GIVE Initiative 2Lexicon Pharmaceuticals to Present at Bio InvestorForum 2Pharmasset Accesses up to $30 Million of Working Capital 2Pharmasset Accesses up to $30 Million of Working Capital 3
(Date:9/30/2014)... (PCE) in drinking water may increase the risk ... new study led by a Boston University School ... in the journal Environmental Health , compared ... 1,766 women in Cape Cod, Ma., where water ... early 1980s by the installation of vinyl-lined asbestos ...
(Date:9/30/2014)... FRANKFURT. Truffles, along ... world. Because they grow underground, people use trained dogs or ... is not only of interest to gourmets. A group of ... University Frankfurt have discovered that the smell of white truffles ... truffle fruiting bodies. , White truffles from the Piedmont region ...
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
Breaking Biology News(10 mins):Contaminated water linked to pregnancy complications, BU study finds 2On the trail of the truffle flavor 2Cancer therapy: Driving cancer cells to suicide 2
... minds about the head size of an ancient human ancestor, ... may have been. Found in Gona, Ethiopia, not far from ... of the famed Australopithecus afarensi "Lucy," the pelvis indicates that ... ago, had a larger birth canal than originally suspected and ...
... , 2008 Arbor Vita Corporation (AVC), a ... its rapid, point-of-care prototype HPV test with a high ... for use throughout the developing world, this diagnostic test ... presentation, "Development of a Rapid Diagnostic Test for Cervical ...
... to make cancer treatment safer A new piece ... (NPL) today will help improve the success rates of ... (linac) will help ensure patients are treated with accurate ... using ionising radiation such as high-energy X-rays or electron ...
Cached Biology News:Arbor Vita presents new data on cancer diagnostic at EUrogin 2NPL unveils new equipment to make cancer treatment safer 2
... you reduce the chance of error. Thats ... Developed using Beckman Coulters extensive experience in ... technology, the CEQ 8000 is a fully ... fills the capillary array with a patented ...
... Chemicon Detergent-OUT Kit is a simple high ... solutions. Removes detergents without significant dilution ... protein solution on the Detergent-OUT Spin column ... columns are suitable for removing detergent from ...
... The standard electrophoresis hood is ... documentation systems. Placed on the ... in place and provides a ... on the lab bench. This ...
... SDS Kit is a simple high performance ... Removes detergents without significant dilution of ... solution on the Detergent-OUT Spin column and ... columns are suitable for removing detergent from ...
Biology Products: